Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

580
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
580
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.8K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.8K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.1K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.1K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.3K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

295
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
295
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.1K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicomycological and Dermoscopic Study of 300 Cases of Dermatophytosis in a Tertiary Care Hospital in Dehradun, India.

Indian journal of dermatology·2026
Same author

Sixteen-Year Interval CT Comparison in Chiari II Malformation After Early Ventriculoperitoneal Shunting: Marked Ventricular Improvement and a Prolonged Seizure-Free Interval.

Cureus·2026
Same author

Effect of presence of rigid impurities in a system of annihilating domain walls with dynamic bias.

Physical review. E·2026
Same author

Hemoglobin SC Sickle Cell Disease Presenting as Acute Ischemic Stroke With Moyamoya Syndrome in an Adult: A Case Report.

Cureus·2025
Same author

Exploring the role of inflammatory cytokines in multiple sclerosis: A comparative perspective.

Multiple sclerosis and related disorders·2025
Same author

Post-vaccinal seronegative autoimmune encephalitis following recombinant zoster vaccination in two immunocompetent patients.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2025
Same journal

Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis.

CNS drugs·2026
Same journal

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same journal

Psychiatric Symptoms Associated with Corticosteroid Use: A Systematic Review and Meta-analysis.

CNS drugs·2026
Same journal

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same journal

Isoform-Specific NaV Modulation in Painful Chemotherapy-Induced Neuropathy: Promise, Limitations, and a Clinical Agenda.

CNS drugs·2026
Same journal

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
See all related articles

Related Experiment Video

Updated: Nov 10, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.6K

Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.

Reshmi Roy1, Alaa A Alotaibi2, Mark S Freedman2

  • 1Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada. reroy@ohri.ca.

CNS Drugs
|April 2, 2021
PubMed
Summary
This summary is machine-generated.

Sphingosine 1-phosphate (S1P) receptor modulators offer oral treatments for multiple sclerosis (MS). Newer, selective S1PR modulators provide improved safety and efficacy for various MS forms.

More Related Videos

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

4.3K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.3K

Related Experiment Videos

Last Updated: Nov 10, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.6K
A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

4.3K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.3K

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Sphingosine 1-phosphate (S1P) is a signaling molecule regulating immune cell trafficking.
  • S1P receptors (S1PRs) are crucial in immune, cardiovascular, and neurological functions.
  • S1PR1 modulation impacts lymphocyte circulation, relevant to multiple sclerosis (MS) pathogenesis.

Purpose of the Study:

  • To review the mechanism of action, pharmacodynamics, kinetics, efficacy, and safety of S1PR modulators for MS.
  • To highlight the development of selective second-generation S1PR modulators.
  • To discuss their application in relapsing-remitting, secondary progressive, and primary progressive MS.

Main Methods:

  • Review of clinical trial data (Phase II and III) for S1PR modulators.
  • Analysis of regulatory approvals and therapeutic applications.
  • Pharmacological and mechanistic evaluation of first- and second-generation agents.

Main Results:

  • Fingolimod, the first oral S1PR modulator (DMT), approved in 2010 for relapsing MS.
  • Second-generation selective S1PR modulators (siponimod, ozanimod, ponesimod, ceralifimod, amiselimod) offer improved safety profiles, particularly reduced cardiac side effects.
  • Siponimod is the first oral DMT approved for active secondary progressive MS.

Conclusions:

  • S1PR modulators represent a significant advancement in oral MS therapy.
  • Selective S1PR modulators offer enhanced safety and efficacy, expanding treatment options for diverse MS subtypes.
  • Ongoing research continues to refine S1PR modulator therapies for autoimmune disorders.